Baseline Visit Blood & Urine Testing

PROCEDURE2 trials

Sponsors

AstraZeneca

Conditions

Lung Cancer

Phase 3

Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC

CompletedNCT02474355

AstraZenecaLung Cancer

Start: 2015-09-18End: 2019-04-18Updated: 2021-11-11

T790M Plasma Testing Methodology Comparison and Clinical Validation

CompletedNCT02997501

AstraZenecaLung Cancer

Start: 2016-12-23End: 2018-10-24Updated: 2024-03-04

Related Papers

Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study

Journal of Cancer Research and Clinical Oncology2023-06-149 citations

A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data

Future Oncology2023-01-019 citations

Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories

JCO Precision Oncology2020-05-1510 citations

Real-World Analysis of the Efficacy of Rebiopsy and <i>EGFR</i> Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer.

2019-06-0121 citations

Predictive and prognostic values of circulating tumor DNA (ctDNA) clearance in osimertinib treated advanced non-small cell lung cancer cohort.

Journal of Clinical Oncology2019-05-204 citations

Molecular landscape of osimertinib resistance revealed by targeted panel sequencing and patient-derived cancer models in non-small cell lung cancer patients

Annals of Oncology2018-10-0110 citations

Real world data of osimertinib in patients with central nervous system (CNS) metastasis in ASTRIS Korean subset

Annals of Oncology2018-10-011 citations

ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2017-05-2016 citations

Detect T790M in cell free tumor DNA of Chinese advanced non-small cell lung cancer adenocarcinoma patients by different platforms and evaluate clinical outcomes of T790M positive patients with osimertinib monotherapy.

Journal of Clinical Oncology2017-05-20

Patients’ willingness to pay for blood-based <i>EGFR</i> <i>T790M</i> testing: Results from a Canadian validation study of circulating DNA <i>T790M</i> testing.

Journal of Clinical Oncology2017-05-20